Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CervoMed (CRVO) Free Cash Flow (2022 - 2025)

CervoMed's Free Cash Flow history spans 9 years, with the latest figure at -$6.5 million for Q3 2025.

  • For Q3 2025, Free Cash Flow fell 33.18% year-over-year to -$6.5 million; the TTM value through Sep 2025 reached -$24.9 million, down 126.21%, while the annual FY2024 figure was -$16.5 million, 121.89% down from the prior year.
  • Free Cash Flow for Q3 2025 was -$6.5 million at CervoMed, up from -$6.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $6.9 million in Q3 2022 and bottomed at -$8.1 million in Q4 2024.
  • The 4-year median for Free Cash Flow is -$2.5 million (2023), against an average of -$2.9 million.
  • The largest YoY upside for Free Cash Flow was 68.67% in 2023 against a maximum downside of 266.55% in 2023.
  • A 4-year view of Free Cash Flow shows it stood at -$692530.0 in 2022, then tumbled by 266.55% to -$2.5 million in 2023, then tumbled by 217.16% to -$8.1 million in 2024, then increased by 19.7% to -$6.5 million in 2025.
  • Per Business Quant, the three most recent readings for CRVO's Free Cash Flow are -$6.5 million (Q3 2025), -$6.5 million (Q2 2025), and -$3.9 million (Q1 2025).